Market Place
Sourcing Support
Singhi Advisors Facilitates Shinryo`s 85% Stake In GMP Technical Solutions
22 Jul 2024 //
INDIANPHARMAPOST
Saptalis pharm`s Generic Cyclosporine Receives Approval in U.S
05 Jul 2024 //
FDA
Harrow Announces 52-Week Data from VEVYE® ESSENCE-2 Open-Label Extension Study
05 Jun 2024 //
BUSINESSWIRE
Deva Holding Generics Cyclosporine Receives Approval In U.S
21 May 2024 //
FDA
Harrow Announces Availability of VEVYE® (Cyclosporine Ophthalmic Solution) 0.1%
11 Jan 2024 //
BUSINESSWIRE
Teva Pharma`s Generic Cyclosporine Receives Approval in the U.S.
14 Dec 2023 //
FDA
Enforcement Report - Week of December 13, 2023
13 Dec 2023 //
FDA
Novartis Issues Voluntary US Nationwide Recall of Two Lots of Sandimmune
24 Nov 2023 //
PR NEWSWIRE
CEQUA 0.09% Phase 4 Data Showed Sustained Improvement
12 Oct 2023 //
PR NEWSWIRE
Enforcement Report - Week of September 27, 2023
27 Sep 2023 //
FDA
Novartis Issues Voluntary Recall of One Lot of Sandimmune Oral Solution
11 Sep 2023 //
PR NEWSWIRE
EMA Accepts Novaliq’s MAA for CyclASol for the Treatment of Dry Eye Disease
24 Aug 2023 //
BUSINESSWIRE
Harrow Acquires U.S. and Canadian Commercial Rights to VEVYE from Novaliq
18 Jul 2023 //
BUSINESSWIRE
Novaliq Announces FDA Approval of VEVYE 0.1% for Treatment of Dry Eye Disease
08 Jun 2023 //
BUSINESSWIRE
Novaliq Announces Presentation of New Scientific Data on Cyclosporine
02 May 2023 //
BUSINESSWIRE
Novaliq Announces Publication of Second Pivotal PIII Trial Data on CyclASol 0.1%
12 Apr 2023 //
BUSINESSWIRE
Enforcement Report - Week of February 1, 2023
01 Feb 2023 //
FDA
Apotex`s Generic Cyclosporine A Receives Approval in the U.S.
12 Jan 2023 //
FDA
Novaliq Announces FDA Acceptance of the New Drug Application for CyclASol
24 Oct 2022 //
BUSINESSWIRE
Enforcement Report - Week of October 5, 2022
05 Oct 2022 //
FDA
Strides Pharma`s Cyclosporine A Receives BLA Approval in the U.S.
02 Aug 2022 //
FDA
Wellspring Ophthalmics Redceives 2nd Patent for Cyclosporine Dry Eye Therapy
20 Jul 2022 //
BUSINESSWIRE
Santen’s Verkazia 0.1% Now Available for Vernal Keratoconjunctivitis
02 May 2022 //
BUSINESSWIRE
Enforcement Report - Week of April 13, 2022
13 Apr 2022 //
FDA
Wellspring Ophthalmics Acquires Cyclosporine Dry Eye Therapy Patent Portfolio
23 Mar 2022 //
BUSINESSWIRE
FDA Confirms Paragraph IV Patent Litigation for Cyclosporine
08 Feb 2022 //
FDA
AbbVie`s blockbuster eye drug Restasis under threat
03 Feb 2022 //
FIERCEPHARMA
Mylan`s Generic Cyclosporine Receives Approval in the U.S.
02 Feb 2022 //
FDA
Sun Pharma introduces Cequa for dry eye treatment with nanomicellar technology
27 Jan 2022 //
PHARMABIZ
Ocular’s drug-eluting insert for dry eye disease misses endpoint
23 Oct 2021 //
YAHOOFINANCE
Recall of one batch of Ikervis Eye Drops, Emulsion 1mg/ml
27 Aug 2021 //
HSA
Verkazia for the Treatment of Severe Vernal Keratoconjunctivitis
30 Jun 2021 //
BUSINESSWIRE
New in corneal transplant rejection: ANSM issues authorisation first eye drop
03 Feb 2021 //
PRESS RELEASE
Santen Announces U.S. FDA Filing Acceptance of NDAfor Cyclosporine
26 Oct 2020 //
PRNEWSWIRE
Evaluating drug distribution and release in ophthalmic emulsions
24 Aug 2020 //
PHARMAEXCIPIENTS
Novartis recalls immunosuppressant Sandimmune, Neoral capsules for packaging
18 Mar 2020 //
PRNEWSWIRE
Lilly and Incyte Announce Top-Line Results from Phase 3 Study (BREEZE-AD4)
27 Jan 2020 //
PR NEWSWIRE
Sun Pharma launches Cequa to treat dry eye disease in US
15 Oct 2019 //
ECONOMIC TIMES
Hey, FTC, unions say: AbbVie-Allergan merger needs a close look
13 Sep 2019 //
FIERCE PHARMA
AbbVie`s rising immunology star Skyrizi scores nod from England`s cost watchdog
16 Jul 2019 //
FIERCE PHARMA
Apotex`s Generic Cyclosporine Receives Approval in US
12 Jul 2019 //
Aldeyra`s eye drug fails pivotal test for rare, inflammatory disease
25 Jun 2019 //
ENDPTS
SCOTUS just turned its back on Allergan’s legal maneuver to take a blow
16 Apr 2019 //
ENDPTS
A Dry Eye treatment aimed at mitochondria
15 Apr 2019 //
FIERCE BIOTECH
Is this the end for Allergan`s Restasis tribal licensing deal?
15 Apr 2019 //
FIERCE PHARMA
Restasis (Cyclosporine) : Allergan vs. Amneal Pharmaceuticals
30 Jan 2019 //
PATENT LITIGATION
Botox maker Allergan`s revenue forecast misses estimates, shares drop
29 Jan 2019 //
REUTERS
Aurinia posts mixed midphase data on would-be Restasis rival
23 Jan 2019 //
FIERCE BIOTECH
Allergan and its Mohawk allies pitch their sovereign immunity case to SCOTUS
18 Jan 2019 //
ENDPTS
Allergan, Mohawk tribe ask for SC review of scrutinized patent case
16 Jan 2019 //
BIOPHARMA DIVE
Enforcement Report - Week of January 9, 2019
09 Jan 2019 //
FDA
FDA Grants Fast Track Designation to the Baricitinib for SLE
22 Dec 2018 //
PR NEWSWIRE
Prescription Alternatives Inc Receives FDA Form 483
20 Dec 2018 //
FDA
SMC accepts four medicines for NHS use
11 Dec 2018 //
PHARMA TIMES
FTC Backs FDA Draft Guidance to Stem Abusive Citizen Petitions
06 Dec 2018 //
RAPS
FDA Parries on Teva 180-Day Exclusivity Suit
13 Nov 2018 //
FDA NEWS
FDA Fires Back Over Teva Suit on Restasis 180 Days of Exclusivity
06 Nov 2018 //
RAPS
